Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

NCT00810485
completedphase_2

ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

NCT00820079
terminatedphase_2

ADX10059 Migraine Prevention Study

NCT00820105

Clinical Trials (3)

Showing 3 of 3 trials
NCT00810485Phase 2

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

Completed
NCT00820079Phase 2

ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

Completed
NCT00820105Phase 2

ADX10059 Migraine Prevention Study

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3